GSK pays Flagship biotech $80M for preclinical neuro pact
1 day ago · GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks. GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
GSK Steps Up Parkinson’s Focus With US Biotech Deal
1 day ago · Listen. 1:49. GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease. GSK will pay $80 ...
New GSK-sponsored survey reveals unique gaps in care and ...
1 day ago · Find out more at gsk.com. Cautionary statement regarding forward-looking statements. GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.
New Data for AREXVY, GSK’s Respiratory Syncytial Virus ...
Oct 24, 2024 · NCT05921903 is a phase IIb, randomized, controlled, open-label, multi-country study to evaluate the immune response and safety of GSK’s RSV vaccine in adults (≥18 years of age) who are ...
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
GSK makes a strong start to 2024 with improving outlook for ...
May 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for Q1 2024; 60p expected for Full Year 2024.
GSK sees strong growth as Haleon split and vaccine drive pays ...
Jan 31 (Reuters) - GSK (GSK.L) beat market estimates for fourth-quarter results on Wednesday, and unveiled an upbeat forecast for 2024 and beyond on the ramp-up of its vaccines and cancer drugs...
GSK raises 2023 outlook boosted by vaccine, HIV drug sales
Jul 26, 2023 · GSK raised its full-year profit and sales guidance on Wednesday after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.